Trial · NCT06786767
Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
NCT06786767, Completed, Chiesi Bulgaria
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting. Trials, record NCT06786767. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06786767
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
- NCT number
- NCT06786767
- Status
- Completed
- Enrollment
- 281 participants, actual
- Lead sponsor
- Chiesi Bulgaria
- Conditions
- Asthma, Asthma Patients, Asthma Bronchiale
- Interventions
- BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg
- First posted
- 2025-01-22
- Last updated
- 2026-03-19
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Asthma Control Test | 6 months | Change (improvement) of Asthma Control Test score, during the 6 months of treatment (Visit 3), compared to the score at baseline. A maximum score of 25 points indicates complete asthma control, while a score less than 16 indicates very poorly controlled asthma. |
| Primary | Asthma Control Test - 2 | 6 months | The percentage of patients achieving an improvement in Asthma Control Test score of 3 points (MCID, minimum clinically important difference) or more, after the 6-month treatment (Visit 3) compared to baseline. A maximum score of 25 points indicates complete asthma control, while a score less than 16 indicates very poorly controlled asthma. |
| Secondary | Asthma Control Test change | 6 months | The percentage of patients achieving an improvement according to asthma control levels (uncontrolled= ACT ≤15; partially controlled= 15\<ACT\<20; controlled 20≤ACT). |
| Secondary | HRQoL | 6 months | Change in Health-related QoL was assessed by measuring the 5-level EuroQoL 5-dimension component (EQ-5D-5L) index score at Visit 3 (6 months), compared to the baseline visit 1 (Week 0), regarding the assessment of the impact of Asthma on the patient's quality of life. (levels 1 to 5; 1 = indication no problem; 5 = indicating unable to/extreme problems). |
| Secondary | Test of Adherence to Inhalers (TAI-12) | 6 months | Change in Test of Adherence to Inhalers (TAI-12) score at Visit 3 (6 months) compared to baseline visit (Visit 1, week 0) regarding adherence to treatment with use of the Trimbow 172/5/9 μg pMDI (50 points = good adherence; 46 to 49 points = intermediate adherence; \< 45 points = poor adherence). |
| Secondary | Lung function | 6 months | Change in spirometry parameters: FEV1, FVC, FEV1/FVC, at Visit 3 (6 months), compared to the baseline Visit 1 (Week 0), with use of the Trimbow 172/5/9 μg pMDI. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06786767
GET https://conductscience.org/api/trials/v1/NCT06786767/registered